Skip to main content
CDC Website

Information Sheet

Benh Viêm Gan B

This information sheet explains what hepatitis B is and what chronic hepatitis B is. It explains why Asian and Pacific Islander Americans are at higher risk, the symptoms of chronic hepatitis B, who is at risk for hepatitis B, and how women can protect themselves and their babies from hepatitis B.

Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection

This information sheet discusses interferon-gamma release assays (IGRAs), which are whole-blood tests used in diagnosing both latent TB infection and TB disease. It notes that two IGRAs have been approved by the US Food and Drug Administration (FDA) and are commercially available in the United States. The information sheet explains how the IGRAs work; the advantages, disadvantages, and limitations of IGRAs; steps in administering these tests; interpretation; recommendations on when to use them; and whether IGRAs can be given to persons receiving vaccinations.

[Hepatitis A Vaccine: What You Need to Know]

This information sheet discusses the hepatitis A vaccine. It explains hepatitis A virus infection, its effect on the liver, and its transmission and symptoms, and advises that a vaccine can prevent the disease. The information sheet lists who should get the vaccine and when, who should not get the vaccine or should wait, whether there are any risks or adverse reactions to the vaccine, different types of reactions, and what to do. It describes the National Vaccine Injury Compensation Program and provides sources of further information.

Hepatit A Asisi: Bilmeniz Gerekenler

This information sheet discusses the hepatitis A vaccine. It explains hepatitis A virus infection, its effect on the liver, and its transmission and symptoms, and advises that a vaccine can prevent the disease. The information sheet lists who should get the vaccine and when, who should not get the vaccine or should wait, whether there are any risks or adverse reactions to the vaccine, different types of reactions, and what to do. It describes the National Vaccine Injury Compensation Program and provides sources of further information.

TB Elimination: Treatment of Latent Tuberculosis Infection: Maximizing Adherence

This information sheet discusses the need for individuals with latent TB infection (LTBI) to get treatment and prevent the progression of LTBI to TB disease. It emphasizes the importance of the health care provider communicating the value of LTBI treatment and of identifying barriers to adherence. The information sheet also lists strategies for maximizing adherence including collaborating with community agencies and partnering with local health departmetns and community based organizations that can provide needed resources.

TB Elimination: Treatment Options for Latent Tuberculosis Infection

This information sheet discusses treatment for individuals with latent tuberculosis infection (LTBI), with the purpose of this treatment being the reduction of the risk that the infection will progress to TB disease. It explains how the health care provider determines whether the individual with a positive tuberculin skin test (TST) or blood test result is a candidate for treatment of LTBI and how the most effective regimen is chosen; presents LTBI treatment regimens; and describes monitoring during treatment, drug-drug interactions, particularly for HIV-infected patients, and side effects.

TB Elimination: BCG Vaccine

This information sheet discusses the bacille Calmette-Guerin (BCG) vaccine for TB disease, which is used in many countries to prevent childhood tuberculous meningitis and miliary disease. It explains why the BCG is not generally recommended for use in the United States; suggests that the BCG should be considered under specific circumstances; and provides recommendations for when the BCG should be used with children and health care workers and contraindications when it should not be used, such as for immunosuppressed persons and pregnant women.

It's Time: Integrate Viral Hepatitis Into Your Work

This information sheet is an agenda for providers who are taking a two-day training program in which they learn to serve persons at high risk for viral hepatitis. This material lists the training objectives and provides training modules, including specific modules targeted for substance use programs. The training can be used in substance use settings, STD/public health settings, HIV/AIDS programs, and correctional settings, as well as used for providers from all four target settings.

Hepatitis B Vaccination Protection

This information sheet discusses the policies and standards of the Occupational Safety and Health Administration (OSHA) concerning hepatitis B and the provisions made for workers who may have occupational exposure to blood or other potentially infectious materials. It explains the duty of the employer to develop an exposure control plan and implement universal precautions and control measures, including Hepatitis B vaccination.

MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations

This information sheet summarizes the key findings of the new analysis of the CDC’s new estimates of the annual number of new HIV infections in the United States. The new analysis was published in the Morbidity and Mortality Weekly Report of September 12, 2008. The results of the analysis shows that among gay and bisexual men, young African Americans and Whites in their 30s and 40s are most affected, African American women are more affected than women of other races, and men account for the majority of new HIV infection among Hispanics/Latinos.
Was this page helpful? Give Feedback